Biotech | May 29, 2022
USFDA approves two Opdivo-based regimens
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Subscribe To Our Newsletter & Stay Updated
